UBS Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-234
| Closed | -$351 | – | 10307 |
|
|
2023
Q1 | $351 | Buy |
+234
| New | +$315 | ﹤0.01% | 9065 |
|
|
2022
Q4 | – | Sell |
-3,699
| Closed | -$7K | – | 11499 |
|
|
2022
Q3 | $7K | Buy |
+3,699
| New | +$10.7K | ﹤0.01% | 8953 |
|
|
2022
Q1 | – | Sell |
-9,701
| Closed | -$45K | – | 11276 |
|
|
2021
Q4 | $45K | Sell |
9,701
-45,027
| -82% | -$281K | ﹤0.01% | 7019 |
|
|
2021
Q3 | $466K | Buy |
54,728
+39,466
| +259% | +$558K | ﹤0.01% | 4785 |
|
|
2021
Q2 | $251K | Sell |
15,262
-38,808
| -72% | -$784K | ﹤0.01% | 5195 |
|
|
2021
Q1 | $1.19M | Buy |
54,070
+52,582
| +3,534% | +$1.43M | ﹤0.01% | 4081 |
|
|
2020
Q4 | $46K | Buy |
1,488
+1,209
| +433% | +$30.6K | ﹤0.01% | 6270 |
|
|
2020
Q3 | $6K | Sell |
279
-4,890
| -95% | -$85.9K | ﹤0.01% | 7258 |
|
|
2020
Q2 | $79K | Sell |
5,169
-1,666
| -24% | -$19.2K | ﹤0.01% | 5494 |
|
|
2020
Q1 | $53K | Sell |
6,835
-7,618
| -53% | -$93.2K | ﹤0.01% | 5794 |
|
|
2019
Q4 | $206K | Buy |
14,453
+5,481
| +61% | +$84.7K | ﹤0.01% | 5594 |
|
|
2019
Q3 | $135K | Buy |
8,972
+7,375
| +462% | +$115K | ﹤0.01% | 5567 |
|
|
2019
Q2 | $23K | Buy |
1,597
+1,565
| +4,891% | +$25K | ﹤0.01% | 6527 |
|
|
2019
Q1 | $1K | Buy |
+32
| New | +$568 | ﹤0.01% | 7591 |
|
UBS Group's TCRR Position: Q2 2023 in Review
UBS Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 234 shares — an estimated $351 sold.
UBS Group first reported a position in TCRR in Q1 2019 and held it in 14 quarters. The position peaked at $1.19M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- UBS Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 234 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $351.
- UBS Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 14 quarters.
- UBS Group's TCR2 Therapeutics Inc. Common Stock position peaked at $1.19M in Q1 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.